Saby George, MD
Medical Oncology · Buffalo, NYNPI 1063686418
Payments from drug & device makers
Across 731 payments — averaging $20,630 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8M
- Merck$4.1M
- E.r. Squibb & Sons, L.L.C.$1.5M
- Seagen Inc.$456K
- Exelixis Inc.$296K
- Pfizer$190K
- plus $574K from 15 others
Across 9 payments — averaging $1290.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $7,967,724 |
| Merck | 149 | $4,091,823 |
| E.r. Squibb & Sons, L.L.C. | 85 | $1,505,988 |
| Seagen Inc. | 16 | $455,842 |
| Exelixis Inc. | 119 | $295,517 |
| Pfizer | 22 | $190,030 |
| AVEO Pharmaceuticals, Inc. | 72 | $150,660 |
| Eisai Inc. | 98 | $139,250 |
| Gilead | 11 | $97,417 |
| Bayer | 39 | $95,442 |
| EMD Serono, Inc. | 16 | $29,283 |
| Coherus Oncology, Inc. | 63 | $24,416 |
| Sanofi | 4 | $12,345 |
| Astellas Pharma Global Development | 3 | $9,472 |
| AstraZeneca | 9 | $6,620 |
| Immunomedics, Inc. | 2 | $2,740 |
| GSK | 1 | $2,175 |
| Janssen Global Services, LLC | 1 | $2,025 |
| Johnson & Johnson | 1 | $1,763 |
| Janssen Scientific Affairs, LLC | 1 | $77 |
| Astellas Pharma US Inc | 1 | $61 |
How this compares
$15,080,670 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Buffalo
- Nikhil KhushalaniBuffalo$9.8M
- Renuka IyerBuffalo$5.5M
- Anthony MatoIthaca$40.3M
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.